达沙替尼继发的非典型后部可逆性脑病综合征。

IF 2.3 Q2 HEMATOLOGY Blood Research Pub Date : 2023-09-30 DOI:10.5045/br.2023.2023057
Amiya Ranjan Nayak, Deepika Yadav, Priyanka Naranje, Jasmita Dass, Pradeep Kumar, Mukul Aggarwal
{"title":"达沙替尼继发的非典型后部可逆性脑病综合征。","authors":"Amiya Ranjan Nayak, Deepika Yadav, Priyanka Naranje, Jasmita Dass, Pradeep Kumar, Mukul Aggarwal","doi":"10.5045/br.2023.2023057","DOIUrl":null,"url":null,"abstract":"with skin involvement (proven by skin biopsy) has been reported twice. Other differential diagnoses of HSTCL include aggressive natural killer cell leukemia (typically negative for surface CD3 on flow cytometry) and T-lymphoblastic leukemia [dim expression of CD45 and surface CD3 with expression of immaturity markers (TdT/CD34/CD1a)] [4, 6, 8]. The disease has an aggressive course, and most cases will relapse. Moreover, there is no known optimal therapy [1, 2, 7]. With conventional chemotherapy, complete remission is uncommon, and most patients die within two years of diagnosis [5, 9]. Long-term remission can be achieved by allogeneic stem cell transplantation, and studies have suggested that both autologous and allogeneic transplants may confer a potential cure for the disease with an estimated 3 years overall survival after allogeneic transplantation of 56% [2, 8]. One major limitation regarding staging and assessing the extent of lymphoma is the unavailability of bone and PET scans for the patient at diagnosis, which makes assessment of response for chemotherapy and evaluation for achievement of remission challenging.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 3","pages":"161-163"},"PeriodicalIF":2.3000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/66/br-58-3-161.PMC10548285.pdf","citationCount":"0","resultStr":"{\"title\":\"Atypical posterior reversible encephalopathy syndrome secondary to dasatinib.\",\"authors\":\"Amiya Ranjan Nayak, Deepika Yadav, Priyanka Naranje, Jasmita Dass, Pradeep Kumar, Mukul Aggarwal\",\"doi\":\"10.5045/br.2023.2023057\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"with skin involvement (proven by skin biopsy) has been reported twice. Other differential diagnoses of HSTCL include aggressive natural killer cell leukemia (typically negative for surface CD3 on flow cytometry) and T-lymphoblastic leukemia [dim expression of CD45 and surface CD3 with expression of immaturity markers (TdT/CD34/CD1a)] [4, 6, 8]. The disease has an aggressive course, and most cases will relapse. Moreover, there is no known optimal therapy [1, 2, 7]. With conventional chemotherapy, complete remission is uncommon, and most patients die within two years of diagnosis [5, 9]. Long-term remission can be achieved by allogeneic stem cell transplantation, and studies have suggested that both autologous and allogeneic transplants may confer a potential cure for the disease with an estimated 3 years overall survival after allogeneic transplantation of 56% [2, 8]. One major limitation regarding staging and assessing the extent of lymphoma is the unavailability of bone and PET scans for the patient at diagnosis, which makes assessment of response for chemotherapy and evaluation for achievement of remission challenging.\",\"PeriodicalId\":46224,\"journal\":{\"name\":\"Blood Research\",\"volume\":\"58 3\",\"pages\":\"161-163\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/66/br-58-3-161.PMC10548285.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5045/br.2023.2023057\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5045/br.2023.2023057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Atypical posterior reversible encephalopathy syndrome secondary to dasatinib.
with skin involvement (proven by skin biopsy) has been reported twice. Other differential diagnoses of HSTCL include aggressive natural killer cell leukemia (typically negative for surface CD3 on flow cytometry) and T-lymphoblastic leukemia [dim expression of CD45 and surface CD3 with expression of immaturity markers (TdT/CD34/CD1a)] [4, 6, 8]. The disease has an aggressive course, and most cases will relapse. Moreover, there is no known optimal therapy [1, 2, 7]. With conventional chemotherapy, complete remission is uncommon, and most patients die within two years of diagnosis [5, 9]. Long-term remission can be achieved by allogeneic stem cell transplantation, and studies have suggested that both autologous and allogeneic transplants may confer a potential cure for the disease with an estimated 3 years overall survival after allogeneic transplantation of 56% [2, 8]. One major limitation regarding staging and assessing the extent of lymphoma is the unavailability of bone and PET scans for the patient at diagnosis, which makes assessment of response for chemotherapy and evaluation for achievement of remission challenging.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Blood Research
Blood Research HEMATOLOGY-
CiteScore
3.70
自引率
0.00%
发文量
64
期刊最新文献
Correction: Hepatitis B surface antigen reverse seroconversion after hematopoietic stem cell transplantation according to the baseline serological marker levels and vaccination status: a single‑center database analysis. Recent advances in and applications of ex vivo drug sensitivity analysis for blood cancers. PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis. Back to basics: the coagulation pathway. Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1